Status:
COMPLETED
Immune Development in Pediatric Transplantation (IMPACT)
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Chronic Kidney Failure
End Stage Renal Disease
Eligibility:
All Genders
1-20 years
Brief Summary
Transplantation is the preferred method of treatment for end-stage renal disease (ESRD) in children. Over the past forty years, the use of newer immunosuppressive drugs has decreased the risk for orga...
Detailed Description
Over the past forty years, the use of increasingly effective immunosuppressive drugs has decreased the risk for organ rejection (acute rejection, AR) considerably, and improved short-term outcomes. Ho...
Eligibility Criteria
Inclusion
- Parent or legal guardian willing to provide informed consent, if necessary
- 1 to 20 years of age (before 21st birthday) at the time of enrollment
- Undergoing renal transplantation
Exclusion
- Need for multi-organ transplantation
- Any prior history of organ transplantation
- Inability or unwillingness of participant of their legal guardian to give written informed consent or comply with study protocol
Key Trial Info
Start Date :
July 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT00951353
Start Date
July 1 2009
End Date
March 1 2013
Last Update
January 3 2019
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California at Los Angeles/ Mattel Children's Hospital
Los Angeles, California, United States
2
Stanford University Medical Center/ Lucille Packard Children's Hospital
Palo Alto, California, United States
3
Emory University/ Children's Healthcare of Atlanta
Atlanta, Georgia, United States